Abstract：
Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.
摘要：
前列腺癌(PC)通常是激素依赖性肿瘤。雄激素剥夺疗法（80多年来一直是转移性疾病的标准护理。随后的研究强调了ADT的功效，即使在早期疾病中，例如在局部疾病中或在生化复发（BCR）的情况下。对PC生物学和ADT抗性机制的认识提高导致了新一代雄激素受体途径抑制剂（ARPI）的开发。最初仅用于对ADT产生抗药性的患者，随后，ARPI在用于转移性激素初治疾病的患者中时显示出有效的效果，并且近年来，在局部疾病和BCR的情况下也对其有效性进行了评估。这篇综述的目的是描述在PC的不同阶段干扰雄激素受体的试剂的当前作用，并指出未来的观点。
